US › Healthcare

Grace Therapeutics, Inc. (GRCE)

US · Healthcare · Biotechnology

$2.18+4.81%
Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue
$0
Revenue YoY
-100.0%
Net profit
$-1.2M
Profit YoY
-230.1%
EPS
$-0.08
EPS estimate
$-0.20

EPS came in at -0.08 against a street estimate of -0.20 — a beat of 60.0%.

Key statistics

Market cap
$33.8M
Forward P/E
2.2
P/B
0.53
Book value
$3.99
EPS (TTM)
$-0.47
52-week high
$5.18
52-week low
$1.79
50-day MA
$2.35
200-day MA
$3.20
Beta
0.37

Analyst view

Analysts rate Grace Therapeutics, Inc. a strong buy (2 buy, 0 hold, 0 sell out of 2) with an average price target of $6.04.

Shareholding

Insiders
23.52%
Institutions
26.52%

Largest institutional holders

FundStake
HPM Partners LLC5.22%
Eversept Partners, LP4.65%
Nantahala Capital Management, LLC4.47%
Bank of America Corp3.04%
Vanguard Capital Management, LLC2.47%
Renaissance Technologies Corp1.50%
Jane Street Group LLC1.03%
Citadel Advisors Llc0.61%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Grace Therapeutics, Inc. — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncNovo Nordisk A/SAmgen IncAbbott LaboratoriesGilead Sciences Inc

Data updated 2026-08-05.